The Latest Cardiac and Vascular News
The TFA Cannula incorporates a distal balloon feature designed to allow blood flow to the cannulated limb during cardiopulmonary bypass VANCOUVER, BC, July 30, 2026 /CNW/ — Total Flow Medical, a medical device company developing solutions for extracorporeal circulation, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) […]
SAN FRANCISCO–(BUSINESS WIRE)– #AI–Cleerly, a leader in advanced cardiac imaging analysis, and Allelica, a precision medicine company specializing in multi-ancestry polygenic risk scores (PRS), today announced a partnership to launch the Cleerly Polygenic Cardiovascular Risk Score Test, powered by Allelica. The test gives physicians a new option to identify and evaluate individuals with an inherited predisposition to coronary plaque. The Cleerly Polygenic Cardiovascular Risk Score Test can be used
Maple Grove, Minnesota, July 29, 2026 – VDyne Inc. (“VDyne”), a privately held medical device company developing an innovative transcatheter tricuspid valve replacement (TTVR) system, today announced that the first patient has been enrolled and treated in the TRIVITA US IDE pivotal study of the TriNovaTM system. The randomized controlled […]
BETHESDA, Md. & TORONTO–(BUSINESS WIRE)–CorVista Health and Analytics For Life today announced FDA clearance of the CorVista® System with Pulmonary Capillary Wedge Pressure (PCWP) Add-On. The PCWP Add-On uses an AI-based algorithm to analyze physiological signals from patients with no history of elevated PCWP or prior right heart catheterization presenting with cardiovascular symptoms, such as chest pain, dyspnea, and fatigue, to indicate the likelihood of elevated PCWP. The clearance marks a
– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter –
The PREVAILS study, now fully enrolled, marks a critical step toward simultaneous regulatory submissions in China and Europe for the next-generation TAVR system HANGZHOU, China, July 23, 2026 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (02500.HK) today announced that patient enrollment…
SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ — Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as “Ribo”) today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive…
Collaboration combines Evogene’s AI-driven computational chemistry platform with ELEO’s proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar cardiovascular market opportunity REHOVOT, Israel and DAEJEON, South Korea, July…
Powered by retrospective real-world data from Dandelion Health, the American Heart Association’s AI Impact Report provides a third-party evaluation of Ultromics’ EchoGo® Heart Failure The independent assessment shows EchoGo® Heart Failure could have identified HFpEF 263 days earlier than…
NATURE trial, a prospective randomized controlled trial comparing the safety and effectiveness of thrombectomy using enVast before conventional PCI versus standard of care alone, was selected for the prestigious Late-Breaking Clinical Trials session at the European Society of Cardiology…
